Literature DB >> 21148079

Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.

Yuan Chen1, Liling Liu, Khanh Nguyen, Adrian J Fretland.   

Abstract

Reaction phenotyping using recombinant human cytochromes P450 (P450) has great utility in early discovery. However, to fully realize the advantages of using recombinant expressed P450s, the extrapolation of data from recombinant systems to human liver microsomes (HLM) is required. In this study, intersystem extrapolation factors (ISEFs) were established for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 using 11 probe substrates, based on substrate depletion and/or metabolite formation kinetics. The ISEF values for CYP2C9, CYP2D6, and CYP3A4 determined using multiple substrates were similar across substrates. When enzyme kinetics of metabolite formation for CYP1A2, 2C9, 2D6, and 3A4 were used, the ISEFs determined were generally within 2-fold of that determined on the basis of substrate depletion. Validation of ISEFs was conducted using 10 marketed drugs by comparing the extrapolated data with published data. The major isoforms responsible for the metabolism were identified, and the contribution of the predominant P450s was similar to that of previously reported data. In addition, phenotyping data from internal compounds, extrapolated using the rhP450-ISEF method, were comparable to those obtained using an HLM-based inhibition assay approach. Moreover, the intrinsic clearance (CL(int)) calculated from extrapolated rhP450 data correlated well with measured HLM CL(int). The ISEF method established in our laboratory provides a convenient tool in early reaction phenotyping for situations in which the HLM-based inhibition approach is limited by low turnover and/or unavailable metabolite formation. Furthermore, this method allows for quantitative extrapolation of HLM intrinsic clearance from rhP450 phenotyping data simultaneously to obtaining the participating metabolizing enzymes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148079     DOI: 10.1124/dmd.110.035147

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

1.  Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

2.  Nonadditivity in human microsomal drug metabolism revealed in a study with coumarin 152, a polyspecific cytochrome P450 substrate.

Authors:  Bikash Dangi; Nadezhda Y Davydova; Nikita E Vavilov; Victor G Zgoda; Dmitri R Davydov
Journal:  Xenobiotica       Date:  2020-07-26       Impact factor: 1.908

3.  Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.

Authors:  Bo Lindmark; Anna Lundahl; Kajsa P Kanebratt; Tommy B Andersson; Emre M Isin
Journal:  Br J Pharmacol       Date:  2018-04-19       Impact factor: 8.739

4.  Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.

Authors:  Huybrecht T'jollyn; Jan Snoeys; Pieter Colin; Jan Van Bocxlaer; Pieter Annaert; Filip Cuyckens; An Vermeulen; Achiel Van Peer; Karel Allegaert; Geert Mannens; Koen Boussery
Journal:  Pharm Res       Date:  2014-07-22       Impact factor: 4.200

5.  Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine.

Authors:  Aki T Heikkinen; Arno Friedlein; Mariette Matondo; Oliver J D Hatley; Aleksanteri Petsalo; Risto Juvonen; Aleksandra Galetin; Amin Rostami-Hodjegan; Ruedi Aebersold; Jens Lamerz; Tom Dunkley; Paul Cutler; Neil Parrott
Journal:  Pharm Res       Date:  2014-07-18       Impact factor: 4.200

6.  How Science Is Driving Regulatory Guidances.

Authors:  Xinning Yang; Jianghong Fan; Lei Zhang
Journal:  Methods Mol Biol       Date:  2021

Review 7.  The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling.

Authors:  Justine Badée; Stephen Fowler; Saskia N de Wildt; Abby C Collier; Stephan Schmidt; Neil Parrott
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

8.  CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.

Authors:  Cong Xu; Sara K Quinney; Yingying Guo; Stephen D Hall; Lang Li; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2013-07-11       Impact factor: 3.922

9.  Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.

Authors:  Huybrecht T'jollyn; Jan Snoeys; Jan Van Bocxlaer; Lies De Bock; Pieter Annaert; Achiel Van Peer; Karel Allegaert; Geert Mannens; An Vermeulen; Koen Boussery
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

10.  Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7.

Authors:  Sara Shum; Nina Isoherranen
Journal:  AAPS J       Date:  2021-01-12       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.